Antiplatelet Therapy for Every Diabetic Person?

ANTONIO NICOLUCCI, MD
EBERHARD STANDL, MD

Until recently, aspirin was recommended by most guidelines for the primary prevention of cardiovascular events in people with diabetes. Recommendations were primarily based on indirect evidence from large trials of populations at high risk of cardiovascular (CV) events. Evidence supporting the efficacy of aspirin therapy in trials of diabetic subjects only is scant. A previous meta-analysis on the efficacy of antiplatelet therapy in the prevention of major CV events found a clear benefit of aspirin overall, but no statistically significant benefit in the subgroup of people with diabetes. No significant reduction in the risk of major CV events with low dose aspirin compared with placebo was found in three additional trials published after that meta-analysis. New meta-analyses incorporating the results of more recent trials agree in indicating that the use of aspirin is associated with a 10% reduction in the risk of major CV events, with no significant effect on CV or all-cause mortality. A differential sex effect is also suggested. The lower-than-expected benefits of antiplatelet therapy make particularly important the evaluation of the risk-benefit balance. Aspirin use is associated with an excess risk of major bleedings of one or two cases for 1,000 individuals treated for 1 year. Such a risk is even higher in the real world setting, exponentially increases with age and is probably increased in the presence of diabetes. Given the currently available limited evidence, it seems reasonable to suggest aspirin treatment only for patients with a 10-year risk >15%, and without contraindications for aspirin.

CV disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes (1). In addition to the concomitant presence of multiple classical CV risk factors that increase atherothrombotic risk (2), diabetes is a “prothrombotic state” associated with accelerated atherosclerosis and inflammation that contribute to the pathogenesis and progression of vascular complications (3). For this reason, interventions to block one or multiple pathways modulating platelet activation and aggregation processes are considered as an essential component of diabetes care to reduce ischemic risk (4).

The use of aspirin for secondary prevention of CV events in patients with coronary or cerebrovascular disease is well established and is supported by solid evidence from the Antithrombotic Trialists’ Collaboration meta-analysis (5). This meta-analysis found that aspirin was beneficial in patients with previous myocardial infarction (MI) or stroke or transient cerebral ischemia. In these high risk populations, aspirin decreases the risk of future events by about one-fifth.

In contrast, the role of aspirin for primary prevention of CV events in individuals with diabetes is controversial, and the debate has been recently refueled by the publication of the results of two randomized clinical trials and several meta-analyses.

From the 1Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy; and the 2Munich Diabetes Research Institute, Munich Helmholtz Centre, Munich, Germany.

Corresponding author: Antonio Nicolucci, nicolucci@negrisud.it.

This publication is based on the presentations at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this supplement were made possible in part by unrestricted educational grants from AstaZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Ethicon Endo-Surgery, Genexer Biotechnology, F. Hoffmann-La Roche, Janssen-Cilag, Johnson & Johnson, Novo Nordisk, Medtronic, and Pfizer.

DOI: 10.2337/dc11-s210
© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

In this review, we will examine the pros and cons of aspirin use in the primary prevention setting in individuals with diabetes.

ASPIRIN FOR PRIMARY PREVENTION OF CV EVENTS

Con

Until recently, aspirin was recommended by almost all existing guidelines for the primary prevention of CV events in people with diabetes, although with some inconsistencies (6). Recommendations seemed to be mainly based on indirect evidence extrapolated from large trials of populations at high risk of CV events, under the assumption that aspirin was effective in individuals at high CV risk and that the presence of diabetes undoubtedly confers an elevated risk of major CVD events. Though correct in principle, this reasoning was not supported by solid evidence derived from trials specifically conducted in people with diabetes (7–13). In 2002, a meta-analysis (287 trials, 135,000 participants) on the efficacy of antiplatelet therapy in the prevention of major CV events found a clear benefit of aspirin overall (22% risk reduction), but no statistically significant benefit in the subgroup of 5,126 participants with diabetes (7% risk reduction) (14). After the publication of the meta-analysis, no significant reduction in the risk of major CV events with low dose aspirin was found in a subgroup analysis of the Primary Prevention Project (10) as well as in three additional trials (11–13). Results of the most recent trials have been considered by some as definitive proof on the lack of aspirin’s efficacy in the primary prevention of CV events (15), but others have raised claims that data are still inconclusive and more trials are warranted (16,17). The persistence of a substantial uncertainty was further confirmed by the publication of two meta-analyses summarizing the results of the trials testing aspirin in individuals with diabetes (18,19).

Overall, aspirin use in primary prevention was associated with a 10% relative reduction in the risk of major CV events (CV death, nonfatal MI, nonfatal stroke), with no clear effect on CV and overall mortality. These findings were further
confirmed by the recent ATT meta-analysis (5), based on individual patient data derived from six large primary prevention trials.

The lower-than-expected benefits of antiplatelet therapy make it particularly important to perform a careful evaluation of the risk-benefit balance. Aspirin use is associated with an increased risk of intracranial and gastrointestinal bleeding. The excess risk associated with the use of low-doses of aspirin is estimated to be one or two cases of major bleedings for 1,000 individuals treated for 1 year (20). Such a risk is even higher in the real world setting (21) and exponentially increases with age, being particularly elevated in the elderly. Further, the recent ATT meta-analysis suggests that diabetes may be associated with individuals having a 55% higher risk of gastrointestinal bleeding and a 70% higher risk of intracranial bleeding compared with individuals without diabetes (5). Therefore, given the lack of specific safety data in individuals with diabetes, the assumption that major side effects of aspirin are rare should be taken with caution.

How should we use this information in clinical practice? From recent studies it can be estimated that the incidence of major CV events in people with diabetes and without prior CV events is between 10 and 20 per 1,000 person-years. Assuming a relative risk reduction associated with aspirin treatment of about 10%, as suggested by the different meta-analyses, 1,000 people need to be treated for 1 year to prevent one or two major CV events. Therefore the expected benefits might not exceed the risk of major bleedings, particularly among people at low-intermediate CV risk or among older patients (aged >70 years) at high risk of bleeding. One can argue that preventing one episode of MI or ischemic stroke is more important than provoking a transient episode of gastrointestinal bleeding; on the other hand, the lack of evidence of benefit of aspirin use on CV mortality might also suggest that antiplatelet therapy only prevents the less severe forms of MI or stroke. We are simply missing too many pieces of crucial information in order to draw definite conclusions.

The more recent data have also led scientific societies to review existing guidelines. Until 2009, the American Diabetes Association (ADA) recommended low doses of aspirin for primary prevention in any individual aged ≥40 years or with additional CV risk factors (22). In 2010, the recommendation has been changed, with the identification of individuals with a 10-year risk of CVD events over 10% as candidates for primary prevention. The ADA further specifies that this includes the vast majority of men aged >50 years and women aged >60 years with an additional risk factor (23). The same recommendation was recently made by a panel convened by the ADA, the American Heart Association, and the American College ofcardiology (24). On the other hand, opposite conclusions were reached by the Scottish Intercollegiate Guidelines Network, which considered existing evidence as insufficient to recommend the use of aspirin for primary prevention in individuals with diabetes (25). The Canadian Diabetes Association also acknowledged the substantial uncertainty surrounding the role of aspirin, leaving the prescription of the drug to individual clinical judgment (26).

Pro

Despite the progress in the treatment of major CV risk factors, diabetes is still associated with a marked increase in the risk of CV morbidity and mortality. Existing epidemiological data are suggestive of a harmful effect of hyperglycemia on CVD risk not only for type 2, but also for type 1 diabetes (27,28). Recent randomized trials, as well as the ATT Collaboration meta-analysis, document that the average 10-year risk of major CV events in individuals with diabetes without established CV disease is around 18%, as compared with 5% in individuals without diabetes (5,28). Given the persisting elevated CV risk and the substantially lower than expected benefits of intensive metabolic and blood pressure control in individuals with long-lasting diabetes and advanced atherosclerotic disease (29–32), all efforts should be devoted to early and intensive intervention on all known CV risk factors. Because of the prothrombotic state associated with diabetes and the variety of documented platelet alterations associated with it, antiplatelet therapy is usually considered as a cornerstone of CVD prevention, and is recommended by the vast majority of existing guidelines. Though supported by a strong pathophysiological rationale, the evidence for the efficacy of aspirin in the primary prevention setting in diabetes is still being debated. Recently, results of the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes trial showed that, after a median follow-up of 4.37 years, aspirin therapy was associated with a (nonsignificant) 20% reduction (hazard ratio 0.80 [95% CI 0.58–1.10]) in the risk of the primary composite end point, including fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, transient ischemic attack, and peripheral arterial disease (12). In a subgroup analysis restricted to individuals aged ≥65 years, a significant reduction in the incidence of the primary end point was documented in patients treated with aspirin as compared with controls (hazard ratio 0.68 [95% CI 0.46–0.99]). Compliance to aspirin therapy at study end was 90%. A major limitation of the study was the inadequate statistical power, determined by a rate of events much lower than expected.

The lack of adequate statistical power also hampered the results of the Prevention of Progression of Arterial Disease and Diabetes study involving patients with asymptomatic peripheral arterial disease (13). The study found no evidence of the benefit of aspirin on CV events and mortality, despite a baseline CVD risk in the study population close to 3% a year. In this trial, the observed event rate was less than half of the anticipated one and the recruitment of 1,276 patients fell short of the planned 1,600. Further to this, only 50% of the patients were still taking aspirin after 5 years.

The results of more recent trials, pooled with previous evidence in two meta-analyses (18,19), suggest that overall aspirin use reduces the risk of major CV events by about 10%. Though of moderate magnitude, this effect would translate into thousands of major CV events avoided if a large proportion of individuals with diabetes were treated. In particular, data from several trials consistently show that antiplatelet therapy substantially reduces the risk of MI in men and is probably beneficial in reducing the risk of ischemic stroke in women. This differential sex effect, initially documented in broader populations (33), has been recently confirmed in individuals with diabetes by two meta-analyses (18,19). In particular, in the meta-analysis by De Berardis et al. (18) the risk of MI was reduced by 43% in men, while a suggestion of benefit for stroke emerged for women, though statistical significance was not reached.

Based on this differential sex effect, the U.S. Preventive Services Task Force has recently updated its guidelines to encourage men aged 45–79 years to use aspirin when the potential benefit on MI
Aspirin and diabetes

outweighs the potential harm and women aged 55–79 years when the potential benefits on ischemic stroke outweighs the potential harm (34).

It remains to be established why the beneficial effect on specific CV outcomes does not translate into a reduction in CV mortality. One plausible explanation is the lack of statistical power of the trials so far conducted and the need for a longer follow-up period. As an example, assuming a mortality rate of 1% a year, 25,000 patients need to be followed-up for 10 years in order to detect a relative risk reduction of 10% (α=0.05; 1−β=0.90).

The role of aspirin in the primary prevention of CV disease in people with diabetes will probably be clarified by ongoing trials, involving overall more than 20,000 individuals with diabetes (Table 1). The large number of events and participants should allow adequately powered subgroup analyses for specific populations such as elderly patients, women, or people with different severity of diabetes.

CONCLUSIONS—As clearly documented by the existing debate and the divergent conclusions of recent guidelines, the role of aspirin for the primary prevention of CV events in individuals with diabetes is far from being elucidated. Ongoing trials are expected to make a great contribution in clarifying whether and for whom antiplatelet therapy is effective in preventing major CV events. Meanwhile, a better understanding of the pathophysiological mechanisms involved in the response of platelets to aspirin, especially in diabetes, may also contribute to the identification of those who are more likely to benefit from antiplatelet treatment. In particular, it remains to be established whether diabetes represents a specific case of “aspirin resistance,” related to accelerated platelet turnover making the 24-h dosing interval inadequate to completely suppress platelet COX-1 (35). Furthermore, to what extent additional factors, such as poor metabolic control, degree of insulin resistance, or duration of diabetes could play role in modulating platelet response to aspirin remains a key priority for our future research agenda in diabetes and CV diseases (3). The safety profile of aspirin in individuals with diabetes also needs to be evaluated with greater attention to the real world setting. Randomized clinical trials are often inadequate to provide reliable information on safety (36,37), and observation of very large populations is

Table 1—Characteristics of randomized trials investigating the efficacy of aspirin in the primary prevention of cardiovascular events in individuals with diabetes

| Study     | Men (Diabetic patients) | Aspirin dose | Duration of Therapy | Aspirin dose (mg/day) | Primary outcome | Major CV events | MI | Stroke | All-case mortality |
|-----------|-------------------------|--------------|---------------------|-----------------------|-----------------|----------------|-----|--------|-------------------|
| PHS (7)   | R, DB, PC               | 533          | 352 mg every other day | 3.7 yrs               | CV mortality    | 0.40 (0.20–0.79) | —   | —      | —                 |
| ETDRS (8) | R, DB, PC               | 56.5         | 630 mg/day          | 3 yrs                  | Major CV events | 1.00 (0.50–1.89) | 1.20 (1.57–1.72) | 1.32 (1.68–2.01) |
| HOT (9)   | R, DB, PC               | 5.0          | 75 mg/day           | 3.8 yrs               | CV death+MI+stroke | 0.80 (0.59–1.12) | 0.80 (0.70–1.21) | 1.20 (1.00–1.59) |
| PPH (10)  | R, DB, PC, F           | 53.0         | 100 mg/day          | 3.6 yrs               | CV death+MI+stroke | 0.80 (0.56–1.13) | 0.90 (0.27–1.58) | 0.80 (0.56–1.21) |
| PPP (11)  | R, DB, PC               | 40.2         | 100 mg/day          | 10 yrs                | CV death+MI+stroke | 0.97 (0.76–1.24) | 1.10 (0.83–1.45) | 0.74 (0.49–1.12) |
| WHS (12)  | R, DB, PC, F           | 44.1         | 100 mg/day          | 6.7 yrs               | CV death+MI+stroke | 0.80 (0.59–1.09) | 0.87 (0.40–1.87) | 0.89 (0.54–1.64) |
| POPADAD (13) | R, DB, PC, F | 550         | 100 mg/day          | 10 yrs                | CV death+MI+stroke | 0.80 (0.59–1.09) | 0.87 (0.40–1.87) | 0.89 (0.54–1.64) |
| JPP (14)  | R, OL                   | 55.0         | 100 mg/day          | 4.37 yrs              | Event driven CV death+MI+stroke | 0.80 (0.59–1.09) | 0.87 (0.40–1.87) | 0.89 (0.54–1.64) |
| ASCEND (15) | R, DB, PC, F | 2,000       | 100 mg/day          | 10 yrs                | Event driven CV death+MI+stroke | 0.80 (0.59–1.09) | 0.87 (0.40–1.87) | 0.89 (0.54–1.64) |
| JAPAD (16) | R, OL                   | 550         | 100 mg/day          | 4.37 yrs              | Event driven CV death+MI+stroke | 0.80 (0.59–1.09) | 0.87 (0.40–1.87) | 0.89 (0.54–1.64) |
| JPPP (17)  | R, OL                   | 55.0         | 100 mg/day          | 4.37 yrs              | Event driven CV death+MI+stroke | 0.80 (0.59–1.09) | 0.87 (0.40–1.87) | 0.89 (0.54–1.64) |

Data are hazard ratio (95% CI) unless otherwise indicated. ASCEND, Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes; ASCEND, A Study of Cardiovascular Events Prevention Trial in Diabetes; PHS, Physicians’ Health Study; ETDRS, Early Treatment Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JAPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin in Diabetes; JPPP, Japanese Primary Prevention Project with Aspirin in the Elderly with One or More Risk Factors of Vascular Events; OL, open label; PC, placebo controlled; PHS, Physicians’ Health Study; POPADAD, Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; R, randomized; WHS, Women’s Health Study.
needed to better estimate the risk profile in different patient subgroups.

In conclusion, while awaiting the results of new studies, we believe that aspirin is not indicated for individuals with a 10-year risk below 10%, although the decision to prescribe it in individuals with a moderate risk (i.e., 10–15%) must be made on an individual patient basis after careful evaluation of the balance between the expected benefits and the significant risk of major bleeding. Finally, given the currently available limited evidence, it seems reasonable to suggest that patients at high intermediate risk (i.e., >15%) and higher, and without contraindications for aspirin, probably warrant treatment.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

References
1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414–1431
2. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 2004;116(Suppl 5A):11S–12S
3. Evangelista V, Totani L, Rotondo S, et al. Prevention of cardiovascular disease in type 2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 2005;93:8–16
4. Angiolillo DJ. Antplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32:531–540
5. Baigent C, Blackwell L, Collins R, et al.; Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860
6. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 2007;28:1925–1930
7. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129–135
8. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1292–1300
9. Hansson L, Zanchetti A, Carruthers SG, et al.; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755–1762
10. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264–3272
11. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304
12. Ogawa H, Nakayama M, Morimoto T, et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134–2141
13. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Sheikh J, Macfarlane P, Gordon D, Pingle M, MacWalter R. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840
14. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86
15. Hiatt WR. Aspirin for prevention of cardiovascular events. BMJ 2008;337:a1806
16. Nicolucci A. Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. JAMA 2008;300:2180–2181
17. Farkouh ME, Fuster V. Diabetes and aspirin: beware of underpowered negative trials. Nat Clin Pract Cardiovasc Med 2009;6:1
18. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531
19. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 2010;87:211–218
20. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomised controlled trials. Am J Med 2006;119:624–638
21. Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006;4:22
22. American Diabetes Association. 2009 Clinical Practice Recommendations. Diabetes Care 2009;32(Suppl 1):S3–S5
23. American Diabetes Association. 2010 Clinical Practice Recommendations. Diabetes Care 2010;33(Suppl 1):S3
24. Pignone M, Alberts MJ, Cowell JA, et al.; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395–1402
25. Scottish Intercollegiate Guidelines Network (SIGN). Publication No. 116. Management of diabetes. March 2010. Available from http://www.sign.ac.uk/guidelines/fulltext/116/index.html. Accessed 13 June 2010.
26. Bhattacharyya OK, Shah BR, Booth GL. Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ 2008;179:920–926
27. Juutilainen A, Lehto S, Rönnemaa T, Pyorälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008;31:714–719
28. Turnbull FM, Abraira C, Anderson RJ, et al.; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–2298
29. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
30. ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Bilott L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompstead S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572
31. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139
32. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2
33. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306–313

34. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:405–410

35. Davì G, Santilli F. Aspirin as antiplatelet agent in diabetes. PROS-. Eur J Intern Med 2010;21:149–153

36. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437–443

37. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756–1761